
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Descartes-08 in Pediatric & Young Adult SLE, ANCA Vasculitis, JMG, JDM
Details : Descartes-08 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Childhood-onset Lupus Erythematosus, Discoid.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 28, 2025
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cartesian Reports 12-Month Benefit from Descartes-08 in MG Phase 2b
Details : Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 08, 2025
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Descartes-08 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cartesian Therapeutics Announces FDA Special Protocol Assessment for AURORA Trial in MG
Details : Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 27, 2025
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cartesian Announces Positive Descartes-08 Data in Myasthenia Gravis and Outlines Phase 3
Details : Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cartesian Receives RPD Designation for Descartes-08 in Juvenile Dermatomyositis
Details : Descartes-08 is a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for Juvenile Dermatomyositis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 09, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Cartesian Doses First Patient in Phase 1 Trial of Descartes-15 mRNA CAR-T Therapy
Details : Descartes-15 is the next-generation autologous anti-BCMA mRNA-engineered mRNA CAR-T cell therapy. It is being investigated for Relapsed/Refractory Multiple Myeloma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cartesian Reports Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis
Details : Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 02, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Leerink Partners
Deal Size : $130.0 million
Deal Type : Private Placement
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
Details : The Company intends to use the net proceeds from the financing to fund its pipeline, which includes Descartes-08, a potential first-in-class mRNA CAR-T for patients with generalized myasthenia gravis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
July 02, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Leerink Partners
Deal Size : $130.0 million
Deal Type : Private Placement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cartesian Therapeutics Doses First Patient in Phase 2 Trial of Descartes-08 for Lupus
Details : Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for SLE.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 02, 2024
Lead Product(s) : Descartes-08
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
